The information on this site is intended to supplement and enhance, not replace, the advice of a physician who is familiar with your medical history. Decisions about your health should always be made ONLY after detailed conversation with your doctor.
Limited Use
[what does this mean?]
Generic drug name:
eplerenone
(e PLARE e none)
Brand name(s):
INSPRA
GENERIC:
not available
FAMILY:
Potassium-sparing Diuretics
Find the drug label by
searching at DailyMed.
Pregnancy and Breast-feeding Warnings [top]
Pregnancy Warning
Eplerenone increased fetal resorptions in animal studies. Tell your doctor if you are pregnant or thinking of becoming pregnant before you use this drug.
Breast-feeding Warning
Eplerenone was excreted in animal milk. It is likely that this drug is also excreted in human milk. Because of the potential for serious adverse effetcs in nursing infants, you should not use this drug while nursing.
Facts About This Drug [top]
Eplerenone (INSPRA) was initially approved by the Food and Drug Administration (FDA) in September 2002 to treat high blood pressure, but the drug’s manufacturer chose not to put the product on the market. Rather, the company opted to wait to market eplerenone until it had also gained approval for improving the survival of stable patients with a damaged left ventricle (large chamber of the heart) and evidence of congestive heart failure after a heart attack. This approval was granted in...
Eplerenone (INSPRA) was initially approved by the Food and Drug Administration (FDA) in September 2002 to treat high blood pressure, but the drug’s manufacturer chose not to put the product on the market. Rather, the company opted to wait to market eplerenone until it had also gained approval for improving the survival of stable patients with a damaged left ventricle (large chamber of the heart) and evidence of congestive heart failure after a heart attack. This approval was granted in October 2003. In 2008, the drug was also approved for hypertension in pediatric patients.[1] However, in 2025, the FDA approved updated drug safety-related labeling changes for eplerenone, which included the statement that “the safety and effectiveness of INSPRA for treatment of hypertension have not been established in pediatric patients.”
The additional approved uses for the drug in 2003 and 2008 allowed eplerenone to be legally advertised as more than just another high blood pressure-lowering drug. This is important because the marketplace for high blood pressure-lowering drugs is crowded, with dozens of competing agents, and eplerenone is not very distinguished among them – the drug is only moderately effective in this regard.
Eplerenone belongs to the family of water pills (or diuretics) known as potassium-sparing diuretics and is most similar to an older drug called spironolactone (ALDACTONE).
Adverse effects
One of the major concerns of potassium-sparing diuretics such as spironolactone and eplerenone is that they can lead to dangerously high levels of potassium (hyperkalemia) that can potentially cause death in the elderly and in persons with poor kidney function.
The professional product labeling (package insert) for eplerenone states: “The principal risk of INSPRA is hyperkalemia. Hyperkalemia can cause serious, sometimes fatal, arrhythmias (heart rhythm disturbances).”[2]
Studies say...
Researchers are consistently unimpressed by the effectiveness of epleronone.
A senior FDA scientist wrote in a Sept. 27, 2002, memo about the drug’s effectiveness and the risk of increasing potassium blood levels: “We have no reason to think eplerenone is anything but a garden-variety antihypertensive [blood pressure lowering drug] of ordinary effectiveness; i.e., there is no reason to accept increased risk [elevated potassium levels] compared to alternative agents.”[3]
The FDA reviewed several clinical trials in which eplerenone was compared directly to other high blood pressure-lowering drugs. Eplerenone was found to be comparable to spironolactone, the thiazide diuretic hydrochlorothiazide (ESIDRIX, HYDRODIURIL, MICROZIDE), and the angiotensin-converting enzyme (ACE) inhibitor enalapril (VASOTEC).
The Medical Letter on Drugs and Therapeutics, an independent source of drug information, concluded its review of eplerenone by saying the drug is “modestly effective for treatment of hypertension.”[4]
A large clinical trial found that adding the drug to the best standard therapy improved the survival of patients who had a heart attack complicated by a damaged left ventricle and heart failure.[5]
This study found that death from all causes was lower in those taking eplerenone (14.4%) than in patients receiving a placebo (16.7%). The absolute difference in risk of dying between the two groups was 2.3%. In other words, 44 patients need to be treated with eplerenone for 16 months to prevent one death.
The downside of eplerenone, as mentioned above, is the risk of developing a serious elevation in blood potassium level, or hyperkalemia. Of those taking eplerenone, 5.5% experienced a serious elevation in their potassium blood level, whereas only 3.9% of those given placebo had a serious episode of hyperkalemia.
However, patients in everyday practice are rarely monitored as carefully as those who participate in trials. In addition, patients were excluded from entering the study if they were taking a potassium-sparing diuretic or had decreased kidney function, both of which increase the risk of hyperkalemia.
The May 2012 issue of Worst Pills, Best Pills News highlighted a British Medical Journal (BMJ) study indicating that patients taking several types of commonly used antihypertensive medications are at increased risk of developing gout, a type of arthritis.
The BMJ study also showed that a small number of other antihypertensive drugs appear to have the opposite effect, decreasing the risk of gout.
All patients should be informed of the risk of gout with diuretics, beta-blockers, angiotensin-converting enzyme inhibitors (ACE inhibitors) and non-losartan angiotensin II receptor blockers (ARBs) when starting these medications or whenever the dose of the medications is increased [6].
The April 2013 issue of Worst Pills, Best Pills News discussed another BMJ study suggesting an increased risk of acute kidney injury (AKI) is associated with combining nonsteroidal anti-inflammatory drugs (NSAIDs) with two antihypertensive drugs: a diuretic plus either an ACE inhibitor or an ARB. The risk was found to be highest during the first 30 days of starting an NSAID in patients who also are already taking a diuretic plus an ACE inhibitor or an ARB.
The study found that patients currently using a triple-therapy combination — a diuretic, an ACE inhibitor or an ARB, and an NSAID — have a 31% greater risk of developing AKI than current users of a diuretic plus an ACE inhibitor or an ARB without an NSAID.[7]
In 2025, as mentioned above, the FDA updated the drug product label of eplerenone to warn that the drug was not shown to be safe and effective for treating hypertension in pediatric patients.[8]
Before You Use This Drug [top]
Do not use if you have or have had:
Tell your doctor if you have or have had:
Tell your doctor about any other drugs you take, including antifungals, diuretics, potassium, herbs, over-the-counter medications, and vitamins.
When You Use This Drug [top]
How to Use This Drug [top]
Interactions with Other Drugs [top]
The following drugs, biologics (e.g., vaccines, therapeutic antibodies), or foods are listed in Evaluations of Drug Interactions 2003 as causing “highly clinically significant” or “clinically significant” interactions when used together with any of the drugs in this section. In some sections with multiple drugs, the interaction may have been reported for one but not all drugs in this section, but we include the interaction because the drugs in this section are similar to one another. We have also included potentially serious interactions listed in the drug’s FDA-approved professional package insert or in published medical journal articles. There may be other drugs, especially those in the families of drugs listed below, that also will react with this drug to cause severe adverse effects. Make sure to tell your doctor and pharmacist the drugs you are taking and tell them if you are taking any of these interacting drugs:
ACCUPRIL, ACCURETIC, ACEON, ADVIL, ALDACTONE, ALEVE, ALTACE, amiloride, ANSAID, benazepril, BIAXIN, CALAN, CAPOTEN, CAPOZIDE, captopril, cilazapril, clarithromycin, CLINORIL, COZAAR, DAYPRO, diclofenac, DIFLUCAN, diflunisal, DIOVAN, DIOVAN HCT, DOLOBID, DYAZIDE, DYRENIUM, EES, EFFER-K, E-MYCIN, enalapril, ERYBID, ERYC, ERYPED, ERY-TAB, ERYTHROCIN, ERYTHROCOT, erythromycin, ESKALITH, etodolac, fenoprofen, floctafenine, fluconazole, flurbiprofen, fosinopril, GLU-K, grapefruit juice, hypercium, HYZAAR, ibuprofen, ILOSONE, ILOTYCIN, INDOCIN, indomethacin, INHIBASE, INVIRASE, ISOPTIN, itraconazole, K1CARE, KALETRA, KAON-CL, KAYLIXIR, K-DUR, K-ELECTROLYTE, ketoconazole, ketoprofen, KLEASE, KLOR-CON, KLORVESS, K-LYTE, K-NORM, KOLYUM, K-TABS, lisinopril, lithium, LITHOBID, LODINE, losartan, LOTENSIN, LOTENSIN HCT, MAVIK, MAXZIDE, meclofenamate, MECLOMEN, mefanamicacid, meloxicam, MICRO-K, MIDAMOR, MOBIC, MODURETIC, moexipril, MONOPRIL, MOTRIN, MY-E, nambutenone, NAPROSYN, naproxen, nefazodone, nelfinavir, NIZORAL, NORVIR, ORUDIS, oxaprozin, PCE, perindopril, piroxicam, PONSTEL, potassium salt substitutes that contain potassium, PRINIVIL, PRINZIDE, quinapril, ramipril, RELAFEN, ritonavir, saquinavir, SERZONE, spironolactone, SPORANOX, SPRIOZIDE, St. John’s wort, sulindac, TAO, TEN-K, tenoxicam, tiaprofenic acid, TOLECTIN, tolmetin, trandolapril, triamterene, TRI-K, troleandomycin, TWIN-K, UNIRETIC, UNIVASC, valsartan, VASERETIC, VASOTEC, verapamil, VIRACEPT, VOLTAREN, WINTROCIN, ZESTORETIC, ZESTRIL.
Adverse Effects [top]
Call your doctor immediately if you experience:
Call your doctor if these symptoms continue:
Periodic Tests[top]
Ask your doctor which of these tests should be done periodically while you are taking this drug:
last reviewed September 30, 2025
Worst Pills, Best Pills is a project of Public Citizen's Health Research Group Group. As an independent, nonprofit organization, we take no corporate or government contributions and accept no advertising. Copyright © 2025 Public Citizen's Health Research Group. All rights reserved.
Login
Subscribe